Anticancer use of nanoparticles as nucleic acid carriers

Journal of Biomedical Nanotechnology

Volumn 10, Issue 9, 2014, Pages 1751-1783

  Gozuacik, D ^a   Yagci Acar, H F ^b   Akkoc, Y ^a   Kosar, A ^a   Dogan Ekici, A Isin ^c   Ekici, Sinan ^d  

^a SABANCI UNIVERSITY   (Turkey)

^b KOÇ UNIVERSITY   (Turkey)

^c YEDITEPE UNIVERSITY   (Turkey)

^d MALTEPE UNIVERSITY   (Turkey)

Author keywords

Cancer; Chemotherapy; Drug; microRNA; Nanocarriers; Nanomedicine; Nanoparticles; RNA interference; shRNA; siRNA; Targeted therapy

Indexed keywords

BIOCOMPATIBILITY; CHEMOTHERAPY; DISEASES; DRUG INTERACTIONS; GENE THERAPY; MEDICAL NANOTECHNOLOGY; MOLECULES; NANOPARTICLES; PROTEINS; RNA;

CANCER; DRUG; MICRORNAS; NANO-CARRIERS; RNA INTERFERENCE; SHRNA; SIRNA; TARGETED THERAPY;

NANOMAGNETICS;

ANTAGOMIR; ANTINEOPLASTIC AGENT; APTAMER; ATELOCOLLAGEN; CARBON NANOTUBE; CHITOSAN; CYCLODEXTRIN DERIVATIVE; DENDRIMER; GOLD NANOPARTICLE; LIPOSOME; MAGNETIC NANOPARTICLE; MICRORNA; NANOCARRIER; NANOPARTICLE; NUCLEIC ACID; QUANTUM DOT; SILICA NANOPARTICLE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; DRUG CARRIER;

BIOCOMPATIBILITY; CANCER GENE THERAPY; CANCER THERAPY; DRUG DELIVERY SYSTEM; HUMAN; NANOTECHNOLOGY; NONHUMAN; REVIEW; RNA INTERFERENCE; ANIMAL; CHEMISTRY; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; HUMANS; NANOPARTICLES; NEOPLASMS; NUCLEIC ACIDS; RNA INTERFERENCE;

EID: 84904886096     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2014.1935     Document Type: Review

References (244)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal, Cancer statistics. CA. Cancer J. Clin. 64, 9 (2014).
2. M. J. Espiritu, A. C. Collier, and J. P. Bingham, A 21st-century approach to age-old problems: The ascension of biologics in clinical therapeutics. Drug Discov. Today (2014).
3. R. L. Schilsky, Personalized medicine in oncology: The future is now. Nat. Rev. Drug. Discov. 9, 363 (2010).
4. M. N. Patel, M. D. Halling-Brown, J. E. Tym, P. Workman, and B. Al-Lazikani, Objective assessment of cancer genes for drug discovery. Nat. Rev. Drug Discov. 12, 35 (2013).
5. D. Hanahan and R. A. Weinberg, Hallmarks of cancer: The next generation. Cell 144, 646 (2011).
6. N. F. Sun, Z. A. Liu, W. B. Huang, A. L. Tian, and S. Y. Hu, The research of nanoparticles as gene vector for tumor gene therapy. Crit. Rev. Oncol. Hematol. 89, 352 (2013).
7. M. Rothe, U. Modlich, and A. Schambach, Biosafety challenges for use of lentiviral vectors in gene therapy. Curr. Gene Ther. 13, 453 (2013).
8. D. R. Corey, RNA learns from antisense. Nat. Chem. Biol. 3, 8 (2007).
9. V. N. Kim, MicroRNA biogenesis: Coordinated cropping and dicing. Nat. Rev. Mol. Cell Biol. 6, 376 (2005).
10. D. E. Golden, V. R. Gerbasi, and E. J. Sontheimer, An inside job for siRNAs. Mol. Cell 31, 309 (2008).
11. M. Ghildiyal and P. D. Zamore, Small silencing RNAs: An expanding universe. Nat. Rev. Genet. 10, 94 (2009).
12. D. H. Kim, M. A. Behlke, S. D. Rose, M. S. Chang, S. Choi, and J. J. Rossi, Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat. Biotechnol. 23, 222 (2005).
13. Y. Maida, M. Yasukawa, M. Furuuchi, T. Lassmann, R. Possemato, N. Okamoto, V. Kasim, Y. Hayashizaki, W. C. Hahn, and K. Masutomi, An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. Nature 461, 230 (2009).
14. N. R. Smalheiser, The search for endogenous siRNAs in the mammalian brain. Exp. Neurol. 235, 455 (2012).
15. K. A. Tekirdag, G. Korkmaz, D. G. Ozturk, R. Agami, and D. Gozuacik, MIR181A regulates starvation- and rapamycininduced autophagy through targeting of ATG5. Autophagy 9, 374 (2013).
16. G. Korkmaz, K. A. Tekirdag, D. G. Ozturk, A. Kosar, O. U. Sezerman, and D. Gozuacik, MIR376A Is a Regulator of Starvation-Induced Autophagy. PLoS One 8, e82556 (2013).
17. D. Castanotto and J. J. Rossi, The promises and pitfalls of RNA-interference-based therapeutics. Nature 457, 426 (2009).
18. E. Iorns, C. J. Lord, N. Turner, and A. Ashworth, Utilizing RNA interference to enhance cancer drug discovery. Nat. Rev. Drug Discov. 6, 556 (2007).
19. M. A. Behlke, Chemical modification of siRNAs for in vivo use. Oligonucleotides 18, 305 (2008).
20. S. D. Rose, D. H. Kim, M. Amarzguioui, J. D. Heidel, M. A. Collingwood, M. E. Davis, J. J. Rossi, and M. A. Behlke, Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res. 33, 4140 (2005).
21. K. Nishina, T. Unno, Y. Uno, T. Kubodera, T. Kanouchi, H. Mizusawa, and T. Yokota, Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Mol. Ther. 16, 734 (2008).
22. F. Czauderna, M. Fechtner, S. Dames, H. Aygun, A. Klippel, G. J. Pronk, K. Giese, and J. Kaufmann, Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 31, 2705 (2003).
23. B. A. Kraynack and B. F. Baker, Small interfering RNAs containing full 2'-O-methylribonucleotide-modified sense strands display Argonaute2/eIF2C2- dependent activity. RNA 12, 163 (2006).
24. F. V. Rivas, N. H. Tolia, J. J. Song, J. P. Aragon, J. Liu, G. J. Hannon, and L. Joshua-Tor, Purified Argonaute2 and an siRNA form recombinant human RISC. Nat. Struct. Mol. Biol. 12, 340 (2005).
25. V. Hornung, M. Guenthner-Biller, C. Bourquin, A. Ablasser, M. Schlee, S. Uematsu, A. Noronha, M. Manoharan, S. Akira, A. de Fougerolles, S. Endres, and G. Hartmann, Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11, 263 (2005).
26. A. D. Judge, G. Bola, A. C. Lee, and I. MacLachlan, Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol. Ther. 13, 494 (2006).
27. A. L. Jackson, J. Burchard, D. Leake, A. Reynolds, J. Schelter, J. Guo, J. M. Johnson, L. Lim, J. Karpilow, K. Nichols, W. Marshall, A. Khvorova, and P. S. Linsley, Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 12, 1197 (2006).
28. D. Bumcrot, M. Manoharan, V. Koteliansky, and D. W. Sah, RNAi therapeutics: A potential new class of pharmaceutical drugs. Nat. Chem. Biol. 2, 711 (2006).
29. A. S. Peek and M. A. Behlke, Design of active small interfering RNAs. Curr. Opin. Mol. Ther. 9, 110 (2007).
30. Y. Pei and T. Tuschl, On the art of identifying effective and specific siRNAs. Nat. Methods 3, 670 (2006).
31. S. Svenson, What nanomedicine in the clinic right now really forms nanoparticles? Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 6, 125 (2014).
32. T. S. Zimmermann, A. C. Lee, A. Akinc, B. Bramlage, D. Bumcrot, M. N. Fedoruk, J. Harborth, J. A. Heyes, L. B. Jeffs, M. John, A. D. Judge, K. Lam, K. McClintock, L. V. Nechev, L. R. Palmer, T. Racie, I. Rohl, S. Seiffert, S. Shanmugam, V. Sood, J. Soutschek, I. Toudjarska, A. J. Wheat, E. Yaworski, W. Zedalis, V. Koteliansky, M. Manoharan, H. P. Vornlocher, and I. MacLachlan, RNAi-mediated gene silencing in non-human primates. Nature 441, 111 (2006).
33. D. V. Morrissey, J. A. Lockridge, L. Shaw, K. Blanchard, K. Jensen, W. Breen, K. Hartsough, L. Machemer, S. Radka, V. Jadhav, N. Vaish, S. Zinnen, C. Vargeese, K. Bowman, C. S. Shaffer, L. B. Jeffs, A. Judge, I. MacLachlan, and B. Polisky, Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 23, 1002 (2005).
34. D. C. Litzinger, A. M. Buiting, N. van Rooijen, and L. Huang, Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim. Biophys. Acta 1190, 99 (1994).
35. A. Akinc, A. Zumbuehl, M. Goldberg, E. S. Leshchiner, V. Busini, N. Hossain, S. A. Bacallado, D. N. Nguyen, J. Fuller, R. Alvarez, A. Borodovsky, T. Borland, R. Constien, A. de Fougerolles, J. R. Dorkin, K. Narayanannair Jayaprakash, M. Jayaraman, M. John, V. Koteliansky, M. Manoharan, L. Nechev, J. Qin, T. Racie, D. Raitcheva, K. G. Rajeev, D. W. Sah, J. Soutschek, I. Toudjarska, H. P. Vornlocher, T. S. Zimmermann, R. Langer, and D. G. Anderson, A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol. 26, 561 (2008).
36. S. C. Semple, A. Akinc, J. Chen, A. P. Sandhu, B. L. Mui, C. K. Cho, D. W. Sah, D. Stebbing, E. J. Crosley, E. Yaworski, I. M. Hafez, J. R. Dorkin, J. Qin, K. Lam, K. G. Rajeev, K. F. Wong, L. B. Jeffs, L. Nechev, M. L. Eisenhardt, M. Jayaraman, M. Kazem, M. A. Maier, M. Srinivasulu, M. J. Weinstein, Q. Chen, R. Alvarez, S. A. Barros, S. De, S. K. Klimuk, T. Borland, V. Kosovrasti, W. L. Cantley, Y. K. Tam, M. Manoharan, M. A. Ciufolini, M. A. Tracy, A. de Fougerolles, I. MacLachlan, P. R. Cullis, T. D. Madden, and M. J. Hope, Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 28, 172 (2010).
37. A. Hoeben, B. Landuyt, M. S. Highley, H. Wildiers, A. T. Van Oosterom, and E. A. De Bruijn, Vascular endothelial growth factor and angiogenesis. Pharmacol. Rev. 56, 549 (2004).
38. Y. Noguchi, J. Wu, R. Duncan, J. Strohalm, K. Ulbrich, T. Akaike, and H. Maeda, Early phase tumor accumulation of macromolecules: A great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res. 89, 307 (1998).
39. A. K. Iyer, G. Khaled, J. Fang, and H. Maeda, Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 11, 812 (2006).
40. Y. Matsumura and H. Maeda, A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387 (1986).
41. T. Ishimoto, Y. Takei, Y. Yuzawa, K. Hanai, S. Nagahara, Y. Tarumi, S. Matsuo, and K. Kadomatsu, Downregulation of monocyte chemoattractant protein-1 involving short interfering RNA attenuates hapten-induced contact hypersensitivity. Mol. Ther. 16, 387 (2008).
42. G. J. Villares, M. Zigler, H. Wang, V. O. Melnikova, H. Wu, R. Friedman, M. C. Leslie, P. E. Vivas-Mejia, G. Lopez-Berestein, A. K. Sood, and M. Bar-Eli, Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res. 68, 9078 (2008).
43. E. Kawata, E. Ashihara, S. Kimura, K. Takenaka, K. Sato, R. Tanaka, A. Yokota, Y. Kamitsuji, M. Takeuchi, J. Kuroda, F. Tanaka, T. Yoshikawa, and T. Maekawa, Administration of PLK- 1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer. Mol. Cancer Ther. 7, 2904 (2008).
44. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori, Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J. Control Release 65, 271 (2000).
45. H. Hatakeyama, H. Akita, and H. Harashima, The polyethyleneglycol dilemma: Advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors. Biol. Pharm. Bull. 36, 892 (2013).
46. F. Iversen, C. Yang, F. Dagnaes-Hansen, D. H. Schaffert, J. Kjems, and S. Gao, Optimized siRNA-PEG conjugates for extended blood circulation and reduced urine excretion in mice. Theranostics 3, 201 (2013).
47. A. Malek, O. Merkel, L. Fink, F. Czubayko, T. Kissel, and A. Aigner, In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes. Toxicol. Appl. Pharmacol. 236, 97 (2009).
48. S. D. Li, S. Chono, and L. Huang, Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles. J. Control Release 126, 77 (2008).
49. K. Remaut, B. Lucas, K. Braeckmans, J. Demeester, and S. C. De Smedt, Pegylation of liposomes favours the endosomal degradation of the delivered phosphodiester oligonucleotides. J. Control Release 117, 256 (2007).
50. G. Adlakha-Hutcheon, M. B. Bally, C. R. Shew, and T. D. Madden, Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity. Nat. Biotechnol. 17, 775 (1999).
51. Y. Sato, H. Hatakeyama, Y. Sakurai, M. Hyodo, H. Akita, and H. Harashima, A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo. J. Control Release 163, 267 (2012).
52. K. Kusumoto, H. Akita, A. El-Sayed, and H. Harashima, Effect of the anchor in polyethylene glycol-lipids on the transfection activity of PEGylated cationic liposomes encapsulating DNA. Biol. Pharm. Bull. 35, 445 (2012).
53. H. M. Aliabadi, B. Landry, C. Sun, T. Tang, and H. Uludag, Supramolecular assemblies in functional siRNA delivery: Where do we stand? Biomaterials 33, 2546 (2012).
54. P. Guo, O. Coban, N. M. Snead, J. Trebley, S. Hoeprich, S. Guo, and Y. Shu, Engineering RNA for targeted siRNA delivery and medical application. Adv. Drug Deliv. Rev. 62, 650 (2010).
55. S. Y. Wu and N. A. McMillan, Lipidic systems for in vivo siRNA delivery. AAPS J. 11, 639 (2009).
56. H. Tian, S. Liu, J. Zhang, S. Zhang, L. Cheng, C. Li, X. Zhang, L. Dai, P. Fan, L. Dai, N. Yan, R. Wang, Y. Wei, and H. Deng, Enhancement of Cisplatin sensitivity in lung cancer xenografts by liposome-mediated delivery of the plasmid expressing small hairpin RNA targeting survivin. J. Biomed. Nanotechnol. 8, 633 (2012).
57. I. R. Gilmore, S. P. Fox, A. J. Hollins, M. Sohail, and S. Akhtar, The design and exogenous delivery of siRNA for posttranscriptional gene silencing. J. Drug Target. 12, 315 (2004).
58. I. R. Gilmore, S. P. Fox, A. J. Hollins, and S. Akhtar, Delivery strategies for siRNA-mediated gene silencing. Curr. Drug Deliv. 3, 147 (2006).
59. S. Akhtar and I. Benter, Toxicogenomics of non-viral drug delivery systems for RNAi: Potential impact on siRNA-mediated gene silencing activity and specificity. Adv. Drug. Deliv. Rev. 59, 164 (2007).
60. B. Ozpolat, A. K. Sood, and G. Lopez-Berestein, Nanomedicine based approaches for the delivery of siRNA in cancer. J. Intern. Med. 267, 44 (2010).
61. S. Dokka, D. Toledo, X. Shi, V. Castranova, and Y. Rojanasakul, Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes. Pharm. Res. 17, 521 (2000).
62. S. Spagnou, A. D. Miller, and M. Keller, Lipidic carriers of siRNA: Differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry (Mosc). 43, 13348 (2004).
63. H. Lv, S. Zhang, B. Wang, S. Cui, and J. Yan, Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control Release 114, 100 (2006).
64. Y. Omidi, A. J. Hollins, M. Benboubetra, R. Drayton, I. F. Benter, and S. Akhtar, Toxicogenomics of non-viral vectors for gene therapy: A microarray study of lipofectin- and oligofectamine-induced gene expression changes in human epithelial cells. J. Drug Target 11, 311 (2003).
65. P. Liu, H. Yu, Y. Sun, M. Zhu, and Y. Duan, A mPEG-PLGA-b-PLL copolymer carrier for adriamycin and siRNA delivery. Biomaterials 33, 4403 (2012).
66. F. Alexis, E. Pridgen, L. K. Molnar, and O. C. Farokhzad, Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 5, 505 (2008).
67. D. E. Owens, 3rd and N. A. Peppas, Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307, 93 (2006).
68. J. Heyes, L. Palmer, K. Bremner, and I. MacLachlan, Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J. Control Release 107, 276 (2005).
69. O. Meyer, D. Kirpotin, K. Hong, B. Sternberg, J. W. Park, M. C. Woodle, and D. Papahadjopoulos, Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides. J. Biol. Chem. 273, 15621 (1998).
70. M. A. Tran, R. J. Watts, and G. P. Robertson, Use of liposomes as drug delivery vehicles for treatment of melanoma. Pigment Cell Melanoma Res 22, 388 (2009).
71. C. N. Landen, Jr, A. Chavez-Reyes, C. Bucana, R. Schmandt, M. T. Deavers, G. Lopez-Berestein, and A. K. Sood, Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65, 6910 (2005).
72. Z. Ma, J. Li, F. He, A. Wilson, B. Pitt, and S. Li, Cationic lipids enhance siRNA-mediated interferon response in mice. Biochem. Biophys. Res. Commun. 330, 755 (2005).
73. J. Jin, K. H. Bae, H. Yang, S. J. Lee, H. Kim, Y. Kim, K. M. Joo, S. W. Seo, T. G. Park, and D. H. Nam, In vivo specific delivery of c-Met siRNA to glioblastoma using cationic solid lipid nanoparticles. Bioconjug. Chem. 22, 2568 (2011).
74. P. Y. Chien, J. Wang, D. Carbonaro, S. Lei, B. Miller, S. Sheikh, S. M. Ali, M. U. Ahmad, and I. Ahmad, Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo. Cancer Gene Ther. 12, 321 (2005).
75. A. Pal, A. Ahmad, S. Khan, I. Sakabe, C. Zhang, U. N. Kasid, and I. Ahmad, Systemic delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer. Int. J. Oncol. 26, 1087 (2005).
76. A. Akinc, M. Goldberg, J. Qin, J. R. Dorkin, C. Gamba-Vitalo, M. Maier, K. N. Jayaprakash, M. Jayaraman, K. G. Rajeev, M. Manoharan, V. Koteliansky, I. Rohl, E. S. Leshchiner, R. Langer, and D. G. Anderson, Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol. Ther. 17, 872 (2009).
77. S. Jiang, A. A. Eltoukhy, K. T. Love, R. Langer, and D. G. Anderson, Lipidoid-coated iron oxide nanoparticles for efficient DNA and siRNA delivery. Nano Lett 13, 1059 (2013).
78. J. A. MacDiarmid and H. Brahmbhatt, Minicells: Versatile vectors for targeted drug or si/shRNA cancer therapy. Curr. Opin. Biotechnol. Delivered by Publishing Technology IP: 203.56.241.128 On: Fri,Copyright: American 22, 909 (2011).
79. J. A. MacDiarmid, N. B. Amaro-Mugridge, J. Madrid-Weiss, I. Sedliarou, S. Wetzel, K. Kochar, V. N. Brahmbhatt, L. Phillips, S. T. Pattison, C. Petti, B. Stillman, R. M. Graham, and H. Brahmbhatt, Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat. Biotechnol. 27, 643 (2009).
80. C. G. Millan, C. I. Colino Gandarillas, M. L. Sayalero Marinero, and J. M. Lanao, Cell-based drug-delivery platforms. Ther. Deliv. 3, 25 (2012).
81. V. Gujrati, S. Kim, S. H. Kim, J. J. Min, H. E. Choy, S. C. Kim, and S. Jon, Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy. ACS Nano 8, 1525 (2014).
82. L. Alvarez-Erviti, Y. Seow, H. Yin, C. Betts, S. Lakhal, and M. J. Wood, Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29, 341 (2011).
83. X. Yuan, S. Naguib, and Z. Wu, Recent advances of siRNA delivery by nanoparticles. Expert. Opin. Drug Deliv. 8, 521 (2011).
84. Y. Wang, Z. Li, Y. Han, L. H. Liang, and A. Ji, Nanoparticlebased delivery system for application of siRNA in vivo. Curr. Drug Metab. 11, 182 (2010).
85. K. A. Howard, Delivery of RNA interference therapeutics using polycation-based nanoparticles. Adv. Drug Deliv. Rev. 61, 710 (2009).
86. F. Takeshita and T. Ochiya, Therapeutic potential of RNA interference against cancer. Cancer Sci 97, 689 (2006).
87. L. Zhang, Z. Chen, and Y. Li, Dual-degradable disulfide-containing PEI-Pluronic/DNA polyplexes: Transfection efficiency and balancing protection and DNA release. Int. J. Nanomedicine 8, 3689 (2013).
88. Y. K. Kim, C. S. Cho, M. H. Cho, and H. L. Jiang, Poly(ester amine) synthesized from trimethylolpropane triacrylate and spermine as an efficient siRNA carrier J. Nanosci. Nanotechnol. 13, 5692 (2013).
89. R. Kircheis, L. Wightman, and E. Wagner, Design and gene delivery activity of modified polyethylenimines. Adv. Drug Deliv. Rev. 53, 341 (2001).
90. A. Kichler, Gene transfer with modified polyethylenimines. J. Gene Med. 6, S3 (2004).
91. A. Aigner, J. Biomed. Biotechnol. 2006, 71659 (2006).
92. O. M. Merkel, A. Beyerle, B. M. Beckmann, M. Zheng, R. K. Hartmann, T. Stoger, and T. H. Kissel, Polymer-related off-target effects in non-viral siRNA delivery. Biomaterials 32, 2388 (2011).
93. D. J. Gary, N. Puri, and Y. Y. Won, Polymer-based siRNA delivery: Perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. J. Control Release 121, 64 (2007).
94. S. M. Moghimi, P. Symonds, J. C. Murray, A. C. Hunter, G. Debska, and A. Szewczyk, A two-stage poly(ethylenimine)-mediated cytotoxicity: Implications for gene transfer/therapy. Mol. Ther. 11, 990 (2005).
95. A. C. Hunter and S. M. Moghimi, Cationic carriers of genetic material and cell death: A mitochondrial tale. Biochim. Biophys. Acta 1797, 1203 (2010).
96. K. A. Woodrow, Y. Cu, C. J. Booth, J. K. Saucier-Sawyer, M. J. Wood, and W. M. Saltzman, Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat. Mater. 8, 526 (2009).
97. K. Singha, R. Namgung, and W. J. Kim, Polymers in small-interfering RNA delivery. Nucleic Acid Ther. 21, 133 (2011).
98. S. Acharya and S. K. Sahoo, PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv. Drug. Deliv. Rev. 63, 170 (2011).
99. Z. W. Wu, C. T. Chien, C. Y. Liu, J. Y. Yan, and S. Y. Lin, Recent progress in copolymer-mediated siRNA delivery. J. Drug Target. 20, 551 (2012).
100. K. Jain and N. K. Jain, Surface engineered dendrimers as antiangiogenic agent and carrier for anticancer drug: Dual attack on cancer. J. Nanosci. Nanotechnol. 14, 5075 (2014).
101. J. Wu, W. Huang, and Z. He, Dendrimers as carriers for siRNA delivery and gene silencing: A review. Scientific World Journal 2013, 630654 (2013).
102. M. L. Patil, M. Zhang, S. Betigeri, O. Taratula, H. He, and T. Minko, Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery. Bioconjug. Chem. 19, 1396 (2008).
103. M. L. Patil, M. Zhang, O. Taratula, O. B. Garbuzenko, H. He, and T. Minko, Internally cationic polyamidoamine PAMAM-OH dendrimers for siRNA delivery: Effect of the degree of quaternization and cancer targeting. Biomacromolecules 10, 258 (2009).
104. A. J. Hollins, Y. Omidi, I. F. Benter, and S. Akhtar, Toxicogenomics of drug delivery systems: Exploiting delivery systeminduced changes in target gene expression to enhance siRNA activity. J. Drug Target. 15, 83 (2007).
105. K. H. Stenzel, T. Miyata, and A. L. Rubin, Collagen as a biomaterial. Annu. Rev. Biophys. Bioeng. 3, 231 (1974).
106. T. Ochiya, K. Honma, F. Takeshita, and S. Nagahara, Atelocollagen- mediated drug discovery technology. Expert. Opin. Drug Discov. 2, 159 (2007).
107. Y. Minakuchi, F. Takeshita, N. Kosaka, H. Sasaki, Y. Yamamoto, M. Kouno, K. Honma, S. Nagahara, K. Hanai, A. Sano, T. Kato, M. Terada, and T. Ochiya, Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res. 32, e109 (2004).
108. T. Koyanagi, Y. Suzuki, Y. Saga, S. Machida, Y. Takei, H. Fujiwara, M. Suzuki, and Y. Sato, In vivo delivery of siRNA targeting vasohibin-2 decreases tumor angiogenesis and suppresses tumor growth in ovarian cancer. Cancer Sci. 104, 1705 (2013).
109. N. Miura, M. Shimizu, W. Shinoda, S. Tsuno, R. Sato, X. Wang, J. Jo, Y. Tabata, and J. Hasegawa, Human RGM249-derived small RNAs potentially regulate tumor malignancy. Nucleic Acid Ther. 23, 332 (2013).
110. S. Ozbas-Turan, C. Aral, L. Kabasakal, M. Keyer-Uysal, and J. Akbuga, Co-encapsulation of two plasmids in chitosan microspheres as a non-viral gene delivery vehicle. J. Pharm. Pharm. Sci. 6, 27 (2003).
111. W. E. Rudzinski and T. M. Aminabhavi, Chitosan as a carrier for targeted delivery of small interfering RNA. Int. J. Pharm. 399, 1 (2010).
112. B. Singh, Y. J. Choi, K. I. Park, T. Akaike, and C. S. Cho, Chemical modification of chitosan with pH-sensitive molecules and specific ligands for efficient DNA transfection and siRNA silencing. J. Nanosci. Nanotechnol. 14, 564 (2014).
113. M. P. Patel, R. R. Patel, and J. K. Patel, Chitosan mediated targeted drug delivery system: A review. J. Pharm. Pharm. Sci. 13, 536 (2010).
114. P. Ghosh, G. Han, M. De, C. K. Kim, and V. M. Rotello, Gold nanoparticles in delivery applications. Adv. Drug Deliv. Rev. 60, 1307 (2008).
115. W. F. Lai, Cyclodextrins in non-viral gene delivery. Biomaterials 35, 401 (2014).
116. J. M. García Fernández, J. M. Benito, and C. O. Mellet, Cyclodextrin-scaffolded glycotransporters for gene delivery. Pure Appl. Chem. 85, 1825 (2013).
117. S. J. Hwang, N. C. Bellocq, and M. E. Davis, Effects of structure of beta-cyclodextrin-containing polymers on gene delivery. Bioconjug. Chem. 12, 280 (2001).
118. M. A. Croyle, B. J. Roessler, C. P. Hsu, R. Sun, and G. L. Amidon, Beta cyclodextrins enhance adenoviral-mediated gene delivery to the intestine. Pharm. Res. 15, 1348 (1998).
119. H. Huang, G. Tang, Q. Wang, D. Li, F. Shen, J. Zhou, and H. Yu, Two novel non-viral gene delivery vectors: Low molecular weight polyethylenimine cross-linked by (2-hydroxypropyl)-beta-cyclodextrin or (2-hydroxypropyl)-gamma- cyclodextrin. Chem. Commun. (Camb.) 2382 (2006).
120. J. D. Heidel, Z. Yu, J. Y. Liu, S. M. Rele, Y. Liang, R. K. Zeidan, D. J. Kornbrust, and M. E. Davis, Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl. Acad. Sci. USA 104, 5715 (2007).
121. S. Hu-Lieskovan, J. D. Heidel, D. W. Bartlett, M. E. Davis, and T. J. Triche, Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 65, 8984 (2005).
122. J. Zhou and J. J. Rossi, Aptamer-targeted cell-specific RNA interference. Silence 1, 4 (2010).
123. J. Zhou, M. L. Bobbin, J. C. Burnett, and J. J. Rossi, Current progress of RNA aptamer-based therapeutics. Front. Genet. 3, 234 (2012).
124. J. Park, M. K. Yu, and S. Jon, Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2, 3 (2012).
125. G. Tiram, A. Scomparin, P. Ofek, and R. Satchi-Fainaro, Interfering Cancer with Polymeric siRNA Nanomedicines. J. Biomed. Nanotechnol. 10, 50 (2014).
126. R. A. Sperling and W. J. Parak, Surface modification, functionalization and bioconjugation of colloidal inorganic nanoparticles. Philos. Trans. A. Math. Phys. Eng. Sci. 368, 1333 (2010).
127. D. Pantarotto, R. Singh, D. McCarthy, M. Erhardt, J. P. Briand, M. Prato, K. Kostarelos, and A. Bianco, Functionalized carbon nanotubes for plasmid DNA gene delivery. Angew. Chem. Int. Ed. Engl. 43, 5242 (2004).
128. D. Cai, J. M. Mataraza, Z. H. Qin, Z. Huang, J. Huang, T. C. Chiles, D. Carnahan, K. Kempa, and Z. Ren, Highly efficient molecular delivery into mammalian cells using carbon nanotube spearing. Nat. Methods 2, 449 (2005).
129. I. B. Neagoe, C. Braicu, C. Matea, C. Bele, G. Florin, K. Gabriel, C. Veronica, and A. Irimie, Efficient siRNA delivery system using carboxilated single-wall carbon nanotubes in cancer treatment. J. Biomed. Nanotechnol. 8, 567 (2012).
130. A. A. Shvedova, E. R. Kisin, D. Porter, P. Schulte, V. E. Kagan, B. Fadeel, and V. Castranova, Mechanisms of pulmonary toxicity and medical applications of carbon nanotubes: Two faces of Janus? Pharmacol. Ther. 121, 192 (2009).
131. C. P. Firme, 3rd and P. R. Bandaru, Toxicity issues in the application of carbon nanotubes to biological systems. Nanomedicine 6, 245 (2010).
132. Z. Liu, S. Tabakman, K. Welsher, and H. Dai, Carbon nanotubes in biology and medicine: In vitro and in vivo detection, imaging and drug delivery. Nano Res. 2, 85 (2009).
133. L. Lacerda, M. A. Herrero, K. Venner, A. Bianco, M. Prato, and K. Kostarelos, Carbon-nanotube shape and individualization critical for renal excretion. Small 4, 1130 (2008).
134. O. Mykhaylyk, D. Vlaskou, N. Tresilwised, P. Pithayanukul, W. Möller, and C. Plank, Magnetic nanoparticle formulations for DNA and siRNA delivery. J. Magn. Magn. Mater. 311, 275 (2007).
135. V. Mulens, M. del Puerto Morales, and D. F. Barber, Development of magnetic nanoparticles for cancer gene therapy: A comprehensive review. ISRN Nanomaterials 2013, 14 (2013).
136. Z. Medarova, W. Pham, C. Farrar, V. Petkova, and A. Moore, In vivo imaging of siRNA delivery and silencing in tumors. Nat. Med. 13, 372 (2007).
137. Y. S. Cho, T. J. Yoon, E. S. Jang, K. Soo Hong, S. Young Lee, O. Ran Kim, C. Park, Y. J. Kim, G. C. Yi, and K. Chang, Cetuximab-conjugated magneto-fluorescent silica nanoparticles for in vivo colon cancer targeting and imaging. Cancer Lett. 299, 63 (2010).
138. Y. Chen, W. Wang, G. Lian, C. Qian, L. Wang, L. Zeng, C. Liao, B. Liang, B. Huang, K. Huang, and X. Shuai, Development of an MRI-visible nonviral vector for siRNA delivery targeting gastric cancer. Int. J. Nanomedicine 7, 359 (2012).
139. L. Wang, J. Shi, H. Zhang, H. Li, Y. Gao, Z. Wang, H. Wang, L. Li, C. Zhang, C. Chen, Z. Zhang, and Y. Zhang, Synergistic anticancer effect of RNAi and photothermal therapy mediated by functionalized single-walled carbon nanotubes. Biomaterials 34, 262 (2013).
140. A. M. Smith, H. Duan, A. M. Mohs, and S. Nie, Bioconjugated quantum dots for in vivo molecular and cellular imaging. Adv. Drug Deliv. Rev. 60, 1226 (2008).
141. M. Ogris, G. Walker, T. Blessing, R. Kircheis, M. Wolschek, and E. Wagner, Tumor-targeted gene therapy: Strategies for the preparation of ligand-polyethylene glycol-polyethylenimine/DNA complexes. J. Control Release 91, 173 (2003).
142. S. Li, Z. Liu, F. Ji, Z. Xiao, M. Wang, Y. Peng, Y. Zhang, L. Liu, Z. Liang, and F. Li, Delivery of quantum Dot-siRNA nanoplexes in SK-N-SH cells for BACE1 gene silencing and intracellular imaging. Mol. Ther. Nucleic Acids 1, e20 (2012).
143. J. Zhao, X. Qiu, Z. Wang, J. Pan, J. Chen, and J. Han, Application of quantum dots as vectors in targeted survivin gene siRNA delivery. Onco. Targets Ther. 6, 303 (2013).
144. Y. Su, Y. He, H. Lu, L. Sai, Q. Li, W. Li, L. Wang, P. Shen, Q. Huang, and C. Fan, The cytotoxicity of cadmium based, aqueous phase-synthesized, quantum dots and its modulation by surface coating. Biomaterials 30, 19 (2009).
145. H. Y. Yang, Y. W. Zhao, Z. Y. Zhang, H. M. Xiong, and S. N. Yu, One-pot synthesis of water-dispersible Ag2S quantum dots with bright fluorescent emission in the second near-infrared window. Nanotechnology 24, 055706 (2013).
146. G. Hong, J. T. Robinson, Y. Zhang, S. Diao, A. L. Antaris, Q. Wang, and H. Dai, In vivo fluorescence imaging with Ag2S quantum dots in the second near-infrared region. Angew. Chem. Int. Ed. Engl. 51, 9818 (2012).
147. Y. Zhang, G. Hong, G. Chen, F. Li, H. Dai, and Q. Wang, Ag2S quantum dot: A bright and biocompatible fluorescent nanoprobe in the second near-infrared window. ACS Nano 6, 3695 (2012).
148. I. Hocaoglu, M. N. Çizmeciyan, R. Erdem, C. Ozen, A. Kurt, A. Sennaroglu, and H. Y. Acar, Development of highly luminescent and cytocompatible near-IR-emitting aqueous Ag2S quantum dots. J. Mater. Chem. 22, 14674 (2012).
149. P. R. Chandran, P. Appadurai, K. Rathinasamy, and N. Sandhyarani, Enhanced cytotoxic effect of doxorubicin loaded multifunctional gold nanoparticle for targeted cancer drug delivery J. Nanopharm. Drug Delivery 1, 289 (2013).
150. P. R. Chandran, P. Appadurai, K. Rathinasamy, and N. Sandhyarani, Enhanced cytotoxic effect of doxorubicin loaded multifunctional gold nanoparticle for targeted cancer drug delivery. J. Nanopharm. Drug Delivery 1, 289 (2013).
151. N. L. Rosi, D. A. Giljohann, C. S. Thaxton, A. K. Lytton-Jean, M. S. Han, and C. A. Mirkin, Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science 312, 1027 (2006).
152. W. H. Kong, K. H. Bae, S. D. Jo, J. S. Kim, and T. G. Park, Cationic lipid-coated gold nanoparticles as efficient and non-cytotoxic intracellular siRNA delivery vehicles. Pharm. Res. 29, 362 (2012).
153. R. Ghosh, L. C. Singh, J. M. Shohet, and P. H. Gunaratne, A gold nanoparticle platform for the delivery of functional microRNAs into cancer cells. Biomaterials 34, 807 (2013).
154. A. Bitar, N. M. Ahmad, H. Fessi, and A. Elaissari, Silica-based nanoparticles for biomedical applications. Drug Discov. Today 17, 1147 (2012).
155. H. Lee, D. Sung, M. Veerapandian, K. Yun, and S. W. Seo, PEGylated polyethyleneimine grafted silica nanoparticles: Enhanced cellular uptake and efficient siRNA delivery. Anal. Bioanal. Chem. 400, 535 (2011).
156. X. Li, Y. Chen, M. Wang, Y. Ma, W. Xia, and H. Gu, A mesoporous silica nanoparticle-PEI-fusogenic peptide system for siRNA delivery in cancer therapy. Biomaterials 34, 1391 (2013).
157. Z. Chen, M. F. Penet, S. Nimmagadda, C. Li, S. R. Banerjee, P. T. Winnard, Jr, D. Artemov, K. Glunde, M. G. Pomper, and Z. M. Bhujwalla, PSMA-targeted theranostic nanoplex for prostate cancer therapy. ACS Nano 6, 7752 (2012).
158. F. Haque, D. Shu, Y. Shu, L. S. Shlyakhtenko, P. G. Rychahou, B. M. Evers, and P. Guo, Ultrastable synergistic tetravalent RNA nanoparticles for targeting to cancers. Nano Today 7, 245 (2012).
159. W. Wei, P. P. Lv, X. M. Chen, Z. G. Yue, Q. Fu, S. Y. Liu, H. Yue, and G. H. Ma, Codelivery of mTERT siRNA and paclitaxel by chitosan-based nanoparticles promoted synergistic tumor suppression. Biomaterials 34, 3912 (2013).
160. S. Ganesh, A. K. Iyer, D. V. Morrissey, and M. M. Amiji, Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors. Biomaterials 34, 3489 (2013).
161. C. Dohmen, D. Edinger, T. Frohlich, L. Schreiner, U. Lachelt, C. Troiber, J. Radler, P. Hadwiger, H. P. Vornlocher, and E. Wagner, Nanosized multifunctional polyplexes for receptor-mediated siRNA delivery. ACS Nano 6, 5198 (2012).
162. S. A. Jensen, E. S. Day, C. H. Ko, L. A. Hurley, J. P. Luciano, F. M. Kouri, T. J. Merkel, A. J. Luthi, P. C. Patel, J. I. Cutler, W. L. Daniel, A. W. Scott, M. W. Rotz, T. J. Meade, D. A. Giljohann, C. A. Mirkin, and A. H. Stegh, Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci. Transl. Med. 5, 209ra152 (2013).
163. H. Arima, A. Yoshimatsu, H. Ikeda, A. Ohyama, K. Motoyama, T. Higashi, A. Tsuchiya, T. Niidome, Y. Katayama, K. Hattori, and T. Takeuchi, Folate-PEG-appended dendrimer conjugate with alpha-cyclodextrin as a novel cancer cell-selective siRNA delivery carrier. Mol. Pharm. 9, 2591 (2012).
164. J. Wei, T. Cheang, B. Tang, H. Xia, Z. Xing, Z. Chen, Y. Fang, W. Chen, A. Xu, S. Wang, and J. Luo, The inhibition of human bladder cancer growth by calcium carbonate/CaIP6 nanocomposite particles delivering AIB1 siRNA. Biomaterials 34, 1246 (2013).
165. T. Kanazawa, K. Sugawara, K. Tanaka, S. Horiuchi, Y. Takashima, and H.
166. M. A. Rahman, A. R. Amin, X. Wang, J. E. Zuckerman, C. H. Choi, B. Zhou, D. Wang, S. Nannapaneni, L. Koenig, Z. Chen, Z. G. Chen, Y. Yen, M. E. Davis, and D. M. Shin, Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth. J. Control Release 159, 384 (2012).
167. J. Guo, J. R. Ogier, S. Desgranges, R. Darcy, and C. O'Driscoll, Anisamide-targeted cyclodextrin nanoparticles for siRNA delivery to prostate tumours in mice. Biomaterials 33, 7775 (2012).
168. M. Shen, F. Gong, P. Pang, K. Zhu, X. Meng, C. Wu, J. Wang, H. Shan, and X. Shuai, An MRI-visible non-viral vector for targeted Bcl-2 siRNA delivery to neuroblastoma. Int. J. Nanomedicine 7, 3319 (2012).
169. D. Lin, Q. Jiang, Q. Cheng, Y. Huang, P. Huang, S. Han, S. Guo, Z. Liang, and A. Dong, Polycation-detachable nanoparticles selfassembled from mPEG-PCL-g-SS-PDMAEMA for in vitro and in vivo siRNA delivery. Acta Biomater. 9, 7746 (2013).
170. L. Zou, X. Song, T. Yi, S. Li, H. Deng, X. Chen, Z. Li, Y. Bai, Q. Zhong, Y. Wei, and X. Zhao, Administration of PLGA nanoparticles carrying shRNA against focal adhesion kinase and CD44 results in enhanced antitumor effects against ovarian cancer. Cancer Gene Ther. 20, 242 (2013).
171. T. Yin, P. Wang, J. Li, R. Zheng, B. Zheng, D. Cheng, R. Li, J. Lai, and X. Shuai, Ultrasound-sensitive siRNA-loaded nanobubbles formed by hetero-assembly of polymeric micelles and liposomes and their therapeutic effect in gliomas. Biomaterials 34, 4532 (2013).
172. H. J. Cho, S. Chong, S. J. Chung, C. K. Shim, and D. D. Kim, Poly-L-arginine and dextran sulfate-based nanocomplex for epidermal growth factor receptor (EGFR) siRNA delivery: Its application for head and neck cancer treatment. Pharm. Res. 29, 1007 (2012).
173. F. Abedini, H. Hosseinkhani, M. Ismail, A. J. Domb, A. R. Omar, P. P. Chong, P. D. Hong, D. S. Yu, and I. Y. Farber, Cationized dextran nanoparticle-encapsulated CXCR4-siRNA enhanced correlation between CXCR4 expression and serum alkaline phosphatase in a mouse model of colorectal cancer. Int. J. Nanomedicine 7, 4159 (2012).
174. F. Yang, W. Huang, Y. Li, S. Liu, M. Jin, Y. Wang, L. Jia, and Z. Gao, Anti-tumor effects in mice induced by survivin-targeted siRNA delivered through polysaccharide nanoparticles. Biomaterials 34, 5689 (2013).
175. L. Chen, Y. Ding, Y. Wang, X. Liu, R. Babu, W. Ravis, and W. Yan, Codelivery of zoledronic acid and doublestranded RNA from core-shell nanoparticles. Int. J. Nanomedicine 8, 137 (2013).
176. H. Jagani, J. V. Rao, V. R. Palanimuthu, R. C. Hariharapura, and S. Gang, A nanoformulation of siRNA and its role in cancer therapy: In vitro and in vivo evaluation. Cell. Mol. Biol. Lett. 18, 120 (2013).
177. L. A. Tobin, Y. Xie, M. Tsokos, S. I. Chung, A. A. Merz, M. A. Arnold, G. Li, H. L. Malech, and K. F. Kwong, Pegylated siRNAloaded calcium phosphate nanoparticle-driven amplification of cancer cell internalization in vivo. Biomaterials 34, 2980 (2013).
178. J. Shen, H. Sun, P. Xu, Q. Yin, Z. Zhang, S. Wang, H. Yu, and Y. Li, Simultaneous inhibition of metastasis and growth of breast cancer by co-delivery of twist shRNA and paclitaxel using pluronic P85-PEI/TPGS complex nanoparticles. Biomaterials 34, 1581 (2013).
179. H. Meng, W. X. Mai, H. Zhang, M. Xue, T. Xia, S. Lin, X. Wang, Y. Zhao, Z. Ji, J. I. Zink, and A. E. Nel, Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano 7, 994 (2013).
180. C. Zheng, M. Zheng, P. Gong, J. Deng, H. Yi, P. Zhang, Y. Zhang, P. Liu, Y. Ma, and L. Cai, Polypeptide cationic micelles mediated co-delivery of docetaxel and siRNA for synergistic tumor therapy. Biomaterials 34, 3431 (2013).
181. Q. Hu, W. Li, X. Hu, J. Shen, X. Jin, J. Zhou, G. Tang, and P. K. Chu, Synergistic treatment of ovarian cancer by co-delivery of survivin shRNA and paclitaxel via supramolecular micellar assembly. Biomaterials 33, 6580 (2012).
182. Y. H. Yu, E. Kim, D. E. Park, G. Shim, S. Lee, Y. B. Kim, C. W. Kim, and Y. K. Oh, Cationic solid lipid nanoparticles for codelivery of paclitaxel and siRNA. Eur. J. Pharm. Biopharm. 80, 268 (2012).
183. Z. J. Deng, S. W. Morton, E. Ben-Akiva, E. C. Dreaden, K. E. Shopsowitz, and P. T. Hammond, Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment. ACS Nano 7, 9571 (2013).
184. X. Q. Liu, M. H. Xiong, X. T. Shu, R. Z. Tang, and J. Wang, Therapeutic delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles inhibits hypoxic tumor growth. Mol. Pharm. 9, 2863 (2012).
185. J. Xiao, X. Duan, Q. Yin, Z. Miao, H. Yu, C. Chen, Z. Zhang, J. Wang, and Y. Li, The inhibition of metastasis and growth of breast cancer by blocking the NF-kappaB signaling pathway using bioreducible PEI-based/p65 shRNA complex nanoparticles. Biomaterials 34, 5381 (2013).
186. R. J. Christie, Y. Matsumoto, K. Miyata, T. Nomoto, S. Fukushima, K. Osada, J. Halnaut, F. Pittella, H. J. Kim, N. Nishiyama, and K. Kataoka, Targeted polymeric micelles for siRNA treatment of experimental cancer by intravenous injection. ACS Nano 6, 5174 (2012).
187. S. Ganesh, A. K. Iyer, F. Gattacceca, D. V. Morrissey, and M. M. Amiji, In vivo biodistribution of siRNA and cisplatin administered using CD44-targeted hyaluronic acid nanoparticles. J. Control Release 172, 699 (2013).
188. H. Shen, C. Rodriguez-Aguayo, R. Xu, V. Gonzalez-Villasana, J. Mai, Y. Huang, G. Zhang, X. Guo, L. Bai, G. Qin, X. Deng, Q. Li, D. R. Erm, B. Aslan, X. Liu, J. Sakamoto, A. Chavez-Reyes, H. D. Han, A. K. Sood, M. Ferrari, and G. Lopez-Berestein, Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin. Cancer Res. 19, 1806 (2013).
189. W. A. May, S. L. Lessnick, B. S. Braun, M. Klemsz, B. C. Lewis, L. B. Lunsford, R. Hromas, and C. T. Denny, The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol. Cell. Biol. 13, 7393 (1993).
190. A. L. Ramon, J. R. Bertrand, H. de Martimprey, G. Bernard, G. Ponchel, C. Malvy, and C. Vauthier, siRNA associated with immunonanoparticles directed against cd99 antigen improves gene expression inhibition in vivo in Ewing's sarcoma. J. Mol. Recognit. 26, 318 (2013).
191. A. Tivnan, W. S. Orr, V. Gubala, R. Nooney, D. E. Williams, C. McDonagh, S. Prenter, H. Harvey, R. Domingo-Fernandez, I. M. Bray, O. Piskareva, C. Y. Ng, H. N. Lode, A. M. Davidoff, and R. L. Stallings, Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS One 7, e38129 (2012).
192. L. Li, X. Xie, J. Luo, M. Liu, S. Xi, J. Guo, Y. Kong, M. Wu, J. Gao, Z. Xie, J. Tang, X. Wang, W. Wei, M. Yang, and M. C. Hung, Targeted expression of miR-34a using the T-VISA system suppresses breast cancer cell growth and invasion. Mol. Ther. 20, 2326 (2012).
193. Q. L. Hu, Q. Y. Jiang, X. Jin, J. Shen, K. Wang, Y. B. Li, F. J. Xu, G. P. Tang, and Z. H. Li, Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC-1 xenograft model. Biomaterials 34, 2265 (2013).
194. M. V. Yigit, S. K. Ghosh, M. Kumar, V. Petkova, A. Kavishwar, A. Moore, and Z. Medarova, Context-dependent differences in miR- 10b breast oncogenesis can be targeted for the prevention and arrest of lymph node metastasis. Oncogene 32, 1530 (2013).
195. J. R. Cubillos-Ruiz, J. R. Baird, A. J. Tesone, M. R. Rutkowski, U. K. Scarlett, A. L. Camposeco-Jacobs, J. Anadon-Arnillas, N. M. Harwood, M. Korc, S. N. Fiering, L. F. Sempere, and J. R. Conejo-Garcia, Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer. Cancer Res. 72, 1683 (2012).
196. I. A. Babar, C. J. Cheng, C. J. Booth, X. Liang, J. B. Weidhaas, W. M. Saltzman, and F. J. Slack, Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc. Natl. Acad. Sci. USA 109, E1695 (2012).
197. A. G. Bader, miR-34 - a microRNA replacement therapy is headed to the clinic. Front. Genet. 3, 120 (2012).
198. L. Piao, M. Zhang, J. Datta, X. Xie, T. Su, H. Li, T. N. Teknos, and Q. Pan, Lipid-based nanoparticle delivery of Pre-miR-107 inhibits the tumorigenicity of head and neck squamous cell carcinoma. Mol. Ther. 20, 1261 (2012).
199. Y. Wang, L. Zhang, S. Guo, A. Hatefi, and L. Huang, Incorporation of histone derived recombinant protein for enhanced disassembly of core-membrane structured liposomal nanoparticles for efficient siRNA delivery. J. Control Release 172, 179 (2013).
200. H. Yu, Y. Zou, L. Jiang, Q. Yin, X. He, L. Chen, Z. Zhang, W. Gu, and Y. Li, Induction of apoptosis in non-small cell lung cancer by downregulation of MDM2 using pH-responsive PMPC-b-PDPA/siRNA complex nanoparticles. Biomaterials 34, 2738 (2013).
201. M. Malhotra, C. Tomaro-Duchesneau, S. Saha, and S. Prakash, Systemic siRNA delivery via peptide-tagged polymeric nanoparticles, targeting PLK1 gene in a mouse xenograft model of colorectal cancer. Int. J. Biomater. 2013, 252531 (2013).
202. J. Shen, Q. Meng, H. Sui, Q. Yin, Z. Zhang, H. Yu, and Y. Li, iRGD Conjugated TPGS mediates codelivery of paclitaxel and survivin shRNA for the reversal of lung cancer resistance. Mol. Pharm. (2013), Epub a head of print, doi: dx.doi.org/10.1021/mp400576f.
203. Z. X. Zhao, S. Y. Gao, J. C. Wang, C. J. Chen, E. Y. Zhao, W. J. Hou, Q. Feng, L. Y. Gao, X. Y. Liu, L. R. Zhang, and Q. Zhang, Self-assembly nanomicelles based on cationic mPEG-PLA-b-Polyarginine(R15) triblock copolymer for siRNA delivery. Biomaterials 33, 6793 (2012).
204. J. Shen, R. Xu, J. Mai, H. C. Kim, X. Guo, G. Qin, Y. Yang, J. Wolfram, C. Mu, X. Xia, J. Gu, X. Liu, Z. W. Mao, M. Ferrari, and H. Shen, High capacity nanoporous silicon carrier for systemic delivery of gene silencing therapeutics. ACS Nano 7, 9867 (2013).
205. W. Ding, F. Wang, J. Zhang, Y. Guo, S. Ju, and H. Wang, A novel local anti-colorectal cancer drug delivery system: Negative lipidoid nanoparticles with a passive target via a size-dependent pattern. Nanotechnology 24, 375101 (2013).
206. B. L. Davidson and P. B. McCray, Jr, Current prospects for RNA interference-based therapies. Nat. Rev. Genet. 12, 329 (2011).
207. A. C. Eifler and C. S. Thaxton, Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study. Methods Mol. Biol. 726, 325 (2011).
208. J. Tabernero, G. I. Shapiro, P. M. LoRusso, A. Cervantes, G. K. Schwartz, G. J. Weiss, L. Paz-Ares, D. C. Cho, J. R. Infante, M. Alsina, M. M. Gounder, R. Falzone, J. Harrop, A. C. White, I. Toudjarska, D. Bumcrot, R. E. Meyers, G. Hinkle, N. Svrzikapa, R. M. Hutabarat, V. A. Clausen, J. Cehelsky, S. V. Nochur, C. Gamba-Vitalo, A. K. Vaishnaw, D. W. Sah, J. A. Gollob, and H. A. Burris, 3rd, First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 3, 406 (2013).
209. M. E. Davis, J. E. Zuckerman, C. H. Choi, D. Seligson, A. Tolcher, C. A. Alabi, Y. Yen, J. D. Heidel, and A. Ribas, Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067 (2010).
210. A. Daka and D. Peer, RNAi-based nanomedicines for targeted personalized therapy. Adv. Drug Deliv. Rev. 64, 1508 (2012).
211. J. Li, Y. Yang, and L. Huang, Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. J. Control Release 158, 108 (2012).
212. T. Suma, K. Miyata, Y. Anraku, S. Watanabe, R. J. Christie, H. Takemoto, M. Shioyama, N. Gouda, T. Ishii, N. Nishiyama, and K. Kataoka, Smart multilayered assembly for biocompatible siRNA delivery featuring dissolvable silica, endosome-disrupting polycation, and detachable PEG. ACS Nano 6, 6693 (2012).
213. X. Z. Yang, S. Dou, Y. C. Wang, H. Y. Long, M. H. Xiong, C. Q. Mao, Y. D. Yao, and J. Wang, Single-step assembly of cationic lipid-polymer hybrid nanoparticles for systemic delivery of siRNA. ACS Nano 6, 4955 (2012).
214. Q. Yin, J. Shen, Z. Zhang, H. Yu, L. Chen, W. Gu, and Y. Li, Multifunctional nanoparticles improve therapeutic effect for breast cancer by simultaneously antagonizing multiple mechanisms of multidrug resistance. Biomacromolecules 14, 2242 (2013).
215. C. Boyer, J. Teo, P. Phillips, R. B. Erlich, S. Sagnella, G. Sharbeen, T. Dwarte, H. T. Duong, D. Goldstein, T. P. Davis, M. Kavallaris, and J. McCarroll, Effective delivery of siRNA into cancer cells and tumors using well-defined biodegradable cationic star polymers. Mol. Pharm. 10, 2435 (2013).
216. D. Lin, Q. Cheng, Q. Jiang, Y. Huang, Z. Yang, S. Han, Y. Zhao, S. Guo, Z. Liang, and A. Dong, Intracellular cleavable poly(2-dimethylaminoethyl methacrylate) functionalized mesoporous silica nanoparticles for efficient siRNA delivery in vitro and in vivo. Nanoscale 5, 4291 (2013).
217. R. F. Place, J. Wang, E. J. Noonan, R. Meyers, M. Manoharan, K. Charisse, R. Duncan, V. Huang, X. Wang, and L. C. Li, Formulation of small activating RNA into lipidoid nanoparticles inhibits xenograft prostate tumor growth by inducing p21 expression. Mol. Ther. Nucleic Acids 1, e15 (2012).
218. J. S. Kim, M. H. Oh, J. Y. Park, T. G. Park, and Y. S. Nam, Protein-resistant, reductively dissociable polyplexes for in vivo systemic delivery and tumor-targeting of siRNA. Biomaterials 34, 2370 (2013).
219. E. A. Ho, M. Osooly, D. Strutt, D. Masin, Y. Yang, H. Yan, and M. Bally, Characterization of long-circulating cationic nanoparticle formulations consisting of a two-stage PEGylation step for the delivery of siRNA in a breast cancer tumor model. J. Pharm. Sci.102, 227 (2013).
220. Y. Ding, W. Wang, M. Feng, Y. Wang, J. Zhou, X. Ding, X. Zhou, C. Liu, R. Wang, and Q. Zhang, A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy. Biomaterials 33, 8893 (2012).
221. J. Shen, Q. Yin, L. Chen, Z. Zhang, and Y. Li, Co-delivery of paclitaxel and survivin shRNA by pluronic P85-PEI/TPGS complex nanoparticles to overcome drug resistance in lung cancer. Biomaterials 33, 8613 (2012).
222. Y. Ren, H. W. Cheung, G. von Maltzhan, A. Agrawal, G. S. Cowley, B. A. Weir, J. S. Boehm, P. Tamayo, A. M. Karst, J. F. Liu, M. S. Hirsch, J. P. Mesirov, R. Drapkin, D. E. Root, J. Lo, V. Fogal, E. Ruoslahti, W. C. Hahn, and S. N. Bhatia, Targeted tumorpenetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Sci. Transl. Med. 4, 147ra12 (2012).
223. M. R. Kang, G. Yang, R. F. Place, K. Charisse, H. Epstein-Barash, M. Manoharan, and L. C. Li, Intravesical delivery of small activating RNA formulated into lipid nanoparticles inhibits orthotopic bladder tumor growth. Cancer Res. 72, 5069 (2012).
224. Q. Yin, J. Shen, L. Chen, Z. Zhang, W. Gu, and Y. Li, Overcoming multidrug resistance by co-delivery of Mdr-1 and survivin-targeting RNA with reduction-responsible cationic poly(beta-amino esters). Biomaterials 33, 6495 (2012).
225. S. J. Lee, M. S. Huh, S. Y. Lee, S. Min, S. Lee, H. Koo, J. U. Chu, K. E. Lee, H. Jeon, Y. Choi, K. Choi, Y. Byun, S. Y. Jeong, K. Park, K. Kim, and I. C. Kwon, Tumor-homing poly-siRNA/glycol chitosan self-cross-linked nanoparticles for systemic siRNA delivery in cancer treatment. Angew. Chem. Int. Ed. Engl. 51, 7203 (2012).
226. Y. Yang, Y. Hu, Y. Wang, J. Li, F. Liu, and L. Huang, Nanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung caner. Mol. Pharm. 9, 2280 (2012).
227. K. M. Choi, K. Kim, I. C. Kwon, I. S. Kim, and H. J. Ahn, Systemic delivery of siRNA by chimeric capsid protein: Tumor targeting and RNAi activity in vivo. Mol. Pharm. 10, 18 (2013).
228. C. A. Taylor, Z. Liu, T. C. Tang, Q. Zheng, S. Francis, T. W. Wang, B. Ye, J. A. Lust, R. Dondero, and J. E. Thompson, Modulation of eIF5A expression using SNS01 nanoparticles inhibits NF-kappaB activity and tumor growth in murine models of multiple myeloma. Mol. Ther. 20, 1305 (2012).
229. M. Kong, X. Li, C. Wang, C. Ding, A. Dong, Q. Duan, and Z. Shen, Tissue distribution and cancer growth inhibition of magnetic lipoplex-delivered type 1 insulin-like growth factor receptor shRNA in nude mice. Acta Biochim. Biophys. Sin. (Shanghai) 44, 591 (2012).
230. J. Yang, S. X. Xie, Y. Huang, M. Ling, J. Liu, Y. Ran, Y. Wang, J. B. Thrasher, C. Berkland, and B. Li, Prostate-targeted biodegradable nanoparticles loaded with androgen receptor silencing constructs eradicate xenograft tumors in mice. Nanomedicine (Lond.) 7, 1297 (2012).
231. F. Pittella, K. Miyata, Y. Maeda, T. Suma, S. Watanabe, Q. Chen, R. J. Christie, K. Osada, N. Nishiyama, and K. Kataoka, Pancreatic cancer therapy by systemic administration of VEGF siRNA contained in calcium phosphate/charge- conversional polymer hybrid nanoparticles. J. Control Release 161, 868 (2012).
232. X. Liu, C. Liu, E. Laurini, P. Posocco, S. Pricl, F. Qu, P. Rocchi, and L. Peng, Efficient delivery of sticky siRNA and potent gene silencing in a prostate cancer model using a generation 5 triethanolamine-core PAMAM dendrimer. Mol. Pharm. 9, 470 (2012).
233. J. Guo, W. P. Cheng, J. Gu, C. Ding, X. Qu, Z. Yang, and C. O'Driscoll, Systemic delivery of therapeutic small interfering RNA using a pH-triggered amphiphilic poly-L-lysine nanocarrier to suppress prostate cancer growth in mice. Eur. J. Pharm. Sci. 45, 521 (2012).
234. J. Beloor, C. S. Choi, H. Y. Nam, M. Park, S. H. Kim, A. Jackson, K. Y. Lee, S. W. Kim, P. Kumar, and S. K. Lee, Arginine-engrafted biodegradable polymer for the systemic delivery of therapeutic siRNA. Biomaterials 33, 1640 (2012).
235. L. Li, R. Wang, D. Wilcox, X. Zhao, J. Song, X. Lin, W. M. Kohlbrenner, S. W. Fesik, and Y. Shen, Tumor vasculature is a key determinant for the efficiency of nanoparticle-mediated siRNA delivery. Gene Ther. 19, 775 (2012).
236. J. M. Li, Y. Y. Wang, W. Zhang, H. Su, L. N. Ji, and Z. W. Mao, Low-weight polyethylenimine cross-linked 2-hydroxypopyl-beta-cyclodextrin and folic acid as an efficient and nontoxic siRNA carrier for gene silencing and tumor inhibition by VEGF siRNA. Int. J. Nanomedicine 8, 2101 (2013).
237. J. Conde, F. Tian, Y. Hernandez, C. Bao, D. Cui, K. P. Janssen, M. R. Ibarra, P. V. Baptista, T. Stoeger, and J. M. de la Fuente, In vivo tumor targeting via nanoparticle-mediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models. Biomaterials 34, 7744 (2013).
238. Y. Zhang, L. Peng, R. J. Mumper, and L. Huang, Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy. Biomaterials 34, 8459 (2013).
239. L. Zeng, J. Li, Y. Wang, C. Qian, Y. Chen, Q. Zhang, W. Wu, Z. Lin, J. Liang, X. Shuai, and K. Huang, Combination of siRNAdirected Kras oncogene silencing and arsenic-induced apoptosis using a nanomedicine strategy for the effective treatment of pancreatic cancer. Nanomedicine 10, 463 (2013).
240. S. J. Lee, J. Y. Yhee, S. H. Kim, I. C. Kwon, and K. Kim, Biocompatible gelatin nanoparticles for tumor-targeted delivery of polymerized siRNA in tumor-bearing mice. J. Control Release 172, 358 (2013).
241. X. Z. Yang, J. Z. Du, S. Dou, C. Q. Mao, H. Y. Long, and J. Wang, Sheddable ternary nanoparticles for tumor acidity-targeted siRNA delivery. ACS Nano 6, 771 (2012).
242. J. B. Lee, K. Zhang, Y. Y. Tam, Y. K. Tam, N. M. Belliveau, V. Y. Sung, P. J. Lin, E. LeBlanc, M. A. Ciufolini, P. S. Rennie, and P. R. Cullis, Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo. Int. J. Cancer 131, E781 (2012).
243. J. Zhou, T. R. Patel, M. Fu, J. P. Bertram, and W. M. Saltzman, Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors. Biomaterials 33, 583 (2012).
244. X. Huang, S. Schwind, B. Yu, R. Santhanam, H. Wang, P. Hoellerbauer, A. Mims, R. Klisovic, A. R. Walker, K. K. Chan, W. Blum, D. Perrotti, J. C. Byrd, C. D. Bloomfield, M. A. Caligiuri, R. J. Lee, R. Garzon, N. Muthusamy, L. J. Lee, and G. Marcucci, Targeted delivery of microRNA-29b by transferrinconjugated anionic lipopolyplex nanoparticles: A novel therapeutic strategy in acute myeloid leukemia. Clin. Cancer Res. 19, 2355 (2013).